Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/27106
Title: Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective.
Austin Authors: Watts, Gerald F;Sullivan, David R;Hare, David L ;Kostner, Karam M;Horton, Ari E;Bell, Damon A;Brett, Tom;Trent, Ronald J;Poplawski, Nicola K;Martin, Andrew C;Srinivasan, Shubha;Justo, Robert N;Chow, Clara K;Pang, Jing
Affiliation: George Institute for Global Health, Sydney, New South Wales, Australia
Westmead Applied Research Centre, The University of Sydney, Sydney, New South Wales, Australia
Department of Cardiology, Westmead Hospital, Sydney, New South Wales, Australia
School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth, Western Australia, Australia
Lipid Disorders Clinic, Cardiometabolic Service, Departments of Cardiology and Internal Medicine, Royal Perth Hospital, Perth, Western Australia, Australia
Department of Chemical Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia
Cardiology
Department of Cardiology, Mater Hospital, University of Queensland, Brisbane, Australia
Monash Heart and Monash Children's Hospital, Monash Health, Melbourne, Victoria, Australia
Monash Cardiovascular Research Centre, Melbourne, Victoria, Australia
Department of Paediatrics, Monash University, Melbourne, Victoria, Australia
Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and Fiona Stanley Hospital Network, Perth, Western Australia, Australia
Department of Clinical Biochemistry, Clinipath Pathology, Perth, Western Australia, Australia
Sonic Genetics, Sonic Pathology, Australia
General Practice and Primary Health Care Research, School of Medicine, University of Notre Dame Australia, Fremantle, Australia
Department of Medical Genomics, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Central Clinical School, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia
Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia
Department General Paediatrics, Perth Children's Hospital, Perth, Western Australia, Australia
Division of Paediatrics, Faculty of Health and Medical Sciences, University of Western Australia, Perth, Western Australia, Australia
Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Sydney, Australia
Discipline of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
Department of Paediatric Cardiology, Queensland Children's Hospital, Brisbane, Queensland, Australia
School of Medicine, University of Queensland, Brisbane, Queensland, Australia
Issue Date: Jun-2021
Date: 2021-02-04
Publication information: American Journal of Preventive Cardiology 2021; 6: 100151
Abstract: Familial hypercholesterolaemia (FH) is a common, heritable and preventable cause of premature coronary artery disease, with significant potential for positive impact on public health and healthcare savings. New clinical practice recommendations are presented in an abridged guidance to assist practitioners in enhancing the care of all patients with FH. Core recommendations are made on the detection, diagnosis, assessment and management of adults, children and adolescents with FH. There is a key role for general practitioners (GPs) working in collaboration with specialists with expertise in lipidology. Advice is given on genetic and cholesterol testing and risk notification of biological relatives undergoing cascade testing for FH; all healthcare professionals should develop skills in genomic medicine. Management is under-pinned by the precepts of risk stratification, adherence to healthy lifestyles, treatment of non-cholesterol risk factors, and appropriate use of low-density lipoprotein (LDL)-cholesterol lowering therapies, including statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Recommendations on service design are provided in the full guidance. These recommendations need to be utilised using judicious clinical judgement and shared decision making with patients and families. Models of care need to be adapted to both local and regional needs and resources. In Australia new government funded schemes for genetic testing and use of PCSK9 inhibitors, as well as the National Health Genomics Policy Framework, will enable adoption of these recommendations. A broad implementation science strategy is, however, required to ensure that the guidance translates into benefit for all families with FH.
URI: https://ahro.austin.org.au/austinjspui/handle/1/27106
DOI: 10.1016/j.ajpc.2021.100151
Journal: American Journal of Preventive Cardiology
PubMed URL: 34327493
Type: Journal Article
Subjects: Adults
Care
Children
Familial hypercholesterolaemia
Guidance
Management
Prevention
Appears in Collections:Journal articles

Show full item record

Page view(s)

36
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.